5-MAPBT

5-MAPBT
Clinical data
Other names	MY400
ATC code	none;
Identifiers
	IUPAC name 1-(1-Benzothiophen-5-yl)-N-methylpropan-2-amine;
CAS Number	2613382-32-2 ;
PubChem CID	165889699;
ChemSpider	103843875;
Chemical and physical data
Formula	C12H15NS
Molar mass	205.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=CC2=C(C=C1)SC=C2)NC;
	InChI InChI=1S/C12H15NS/c1-9(13-2)7-10-3-4-12-11(8-10)5-6-14-12/h3-6,8-9,13H,7H2,1-2H3; Key:SKSFWFUEBKJIAJ-UHFFFAOYSA-N;

5-MAPBT (5-methylaminopropylbenzothiophene) is an empathogenic drug of the benzothiophene group. It is closely related to 5-MAPB but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran.^[2]

It has been patented by Tactogen as an entactogen for potential use as a medicine.^[2]

References

^ Mydecine (5 January 2024). "Novel short-acting psychoactive compounds of the mdma class". Google Patents. Retrieved 23 October 2024.
^ ^a ^b WO 2022/010937, Baggott M, "Advantageous benzothiophene compositions for mental disorders or enhancement.", published 13 January 2022, assigned to Tactogen Inc.

[US20240197679A1-1] Mydecine (5 January 2024). "Novel short-acting psychoactive compounds of the mdma class". Google Patents. Retrieved 23 October 2024.

[WO2022010937A1-2] WO 2022/010937, Baggott M, "Advantageous benzothiophene compositions for mental disorders or enhancement.", published 13 January 2022, assigned to Tactogen Inc.

[1]

[2]

See also

References